{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:05:26Z","timestamp":1785409526049,"version":"3.56.0"},"posted":{"date-parts":[[2025,10,9]]},"group-title":"Cancer Biology","reference-count":63,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"funder":[{"award":["R01CA279968"],"award-info":[{"award-number":["R01CA279968"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>Cancer therapies are typically effective in subsets of patients, reflecting the molecular diversity of cancers and motivating the need for predictive biomarkers of response. Biomarker-guided therapy is increasingly useful in oncology, yet biomarker discovery remains complicated by the large number of molecular features that make it difficult to distinguish causal determinants from spurious associations. To address this challenge, we combined functional genomic screening, proteomics, and drug sensitivity profiling to discover response biomarkers for a number of therapies used in the treatment of Peripheral T-Cell Lymphomas (PTCL). First, we used genome-wide CRISPR-dCas9 interference screens in PTCL cells under drug treatment to identify a shortlist of genes whose knockdown directly increases or decreases drug sensitivity. Next, we profiled drug responses across a diverse panel of 30 PTCL cultures and, from the shortlist, identified genes whose protein abundance correlated with drug sensitivity. Genes detected by both approaches are causal determinants of drug response and correlates of drug response across the panel of lymphoma cultures, making them promising candidates for predictive biomarkers. Basal expression of the reduced folate carrier SLC19A1 was a strong predictor of pralatrexate sensitivity, consistent with its role as the primary transporter for pralatrexate uptake. Simulated clinical trials predicted that biomarker-guided patient selection could improve the power to detect significant benefit of adding pralatrexate to frontline chemotherapy in PTCL. These findings illustrate how the causal insights of functional genetic screens can augment correlative studies to identify biomarkers of drug response, and suggest the potential for precise use of pralatrexate for PTCL.<\/jats:p>","DOI":"10.1101\/2025.10.08.681217","type":"posted-content","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:20:16Z","timestamp":1760044816000},"source":"Crossref","is-referenced-by-count":0,"title":["Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3404-0939","authenticated-orcid":false,"given":"Jacob C.","family":"Pantazis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-3539","authenticated-orcid":false,"given":"Amy E.","family":"Pomeroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-7028","authenticated-orcid":false,"given":"Adam C.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025101408301276000_2025.10.08.681217v1.1","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/cam4.3732","article-title":"Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis","volume":"10","year":"2021","journal-title":"Cancer Med"},{"key":"2025101408301276000_2025.10.08.681217v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"2025101408301276000_2025.10.08.681217v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"2025101408301276000_2025.10.08.681217v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408440"},{"key":"2025101408301276000_2025.10.08.681217v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"2025101408301276000_2025.10.08.681217v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"2025101408301276000_2025.10.08.681217v1.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"2025101408301276000_2025.10.08.681217v1.8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma\u22c6","volume":"33","year":"2022","journal-title":"Annals of Oncology"},{"key":"2025101408301276000_2025.10.08.681217v1.9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0235"},{"key":"2025101408301276000_2025.10.08.681217v1.10","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1986"},{"key":"2025101408301276000_2025.10.08.681217v1.11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nchembio.2010","article-title":"Chemical probes: The many genes of drug mechanism","volume":"12","year":"2016","journal-title":"Nature Chemical Biology"},{"key":"2025101408301276000_2025.10.08.681217v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804385"},{"key":"2025101408301276000_2025.10.08.681217v1.13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00339"},{"key":"2025101408301276000_2025.10.08.681217v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/nature11005"},{"key":"2025101408301276000_2025.10.08.681217v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-022-00996-7"},{"key":"2025101408301276000_2025.10.08.681217v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.029"},{"key":"2025101408301276000_2025.10.08.681217v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09940-1"},{"key":"2025101408301276000_2025.10.08.681217v1.18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/his.15376","article-title":"Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets","volume":"86","year":"2025","journal-title":"Histopathology"},{"key":"2025101408301276000_2025.10.08.681217v1.19","doi-asserted-by":"crossref","unstructured":"Foster, C. & Kuruvilla, J . Treatment approaches in relapsed or refractory peripheral T-cell lymphomas. F1000Res 9, F1000 Faculty Rev-1091 (2020).","DOI":"10.12688\/f1000research.22257.1"},{"key":"2025101408301276000_2025.10.08.681217v1.20","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/bloodadvances.2023010441","article-title":"Pooled analysis of pralatrexate single-agent studies in patients with relapsed\/refractory peripheral T-cell lymphoma","volume":"8","year":"2024","journal-title":"Blood Advances"},{"key":"2025101408301276000_2025.10.08.681217v1.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.4207"},{"key":"2025101408301276000_2025.10.08.681217v1.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"2025101408301276000_2025.10.08.681217v1.23","unstructured":"NCCN Clinical Practice Guidelines in Oncology,T-Cell Lymphoma Guidelines V.2.2025."},{"key":"2025101408301276000_2025.10.08.681217v1.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"2025101408301276000_2025.10.08.681217v1.25","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial","volume":"41","year":"2023","journal-title":"Cancer Cell"},{"key":"2025101408301276000_2025.10.08.681217v1.26","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24203"},{"key":"2025101408301276000_2025.10.08.681217v1.27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-pathol-020117-043821","article-title":"Pathogenesis of Peripheral T Cell Lymphoma","volume":"13","year":"2018","journal-title":"Annual Review of Pathology: Mechanisms of Disease"},{"key":"2025101408301276000_2025.10.08.681217v1.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"2025101408301276000_2025.10.08.681217v1.29","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","year":"2020","journal-title":"Blood Advances"},{"key":"2025101408301276000_2025.10.08.681217v1.30","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.055723"},{"key":"2025101408301276000_2025.10.08.681217v1.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04356-9"},{"key":"2025101408301276000_2025.10.08.681217v1.32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1359-4117.2002.01039.x","article-title":"A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer","volume":"2","year":"2002","journal-title":"Journal of Experimental Therapeutics and Oncology"},{"key":"2025101408301276000_2025.10.08.681217v1.33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00280-016-3142-3","article-title":"Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed\/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment","volume":"78","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025101408301276000_2025.10.08.681217v1.34","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0679-9"},{"key":"2025101408301276000_2025.10.08.681217v1.35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/11532970-000000000-00000","article-title":"Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients: Impact of Genetic Polymorphisms","volume":"49","year":"2010","journal-title":"Clinical Pharmacokinetics"},{"key":"2025101408301276000_2025.10.08.681217v1.36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1385\/MO:19:4:261","article-title":"Pharmacokinetics of Oxaliplatin in Humans","volume":"19","year":"2002","journal-title":"MO"},{"key":"2025101408301276000_2025.10.08.681217v1.37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1307002110"},{"key":"2025101408301276000_2025.10.08.681217v1.38","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0230"},{"key":"2025101408301276000_2025.10.08.681217v1.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"2025101408301276000_2025.10.08.681217v1.40","doi-asserted-by":"crossref","first-page":"3123.1","DOI":"10.1182\/blood-2024-197991","article-title":"Trial in Progress: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-Cop to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma \u2013 Crescendo","volume":"144","year":"2024","journal-title":"Blood"},{"key":"2025101408301276000_2025.10.08.681217v1.41","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.19760"},{"key":"2025101408301276000_2025.10.08.681217v1.42","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12169"},{"key":"2025101408301276000_2025.10.08.681217v1.43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13059-020-1940-8","article-title":"Systematic functional identification of cancer multi-drug resistance genes","volume":"21","year":"2020","journal-title":"Genome Biol"},{"key":"2025101408301276000_2025.10.08.681217v1.44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4428"},{"key":"2025101408301276000_2025.10.08.681217v1.45","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1517\/14656566.2010.489552","article-title":"Pralatrexate: basic understanding and clinical development","volume":"11","year":"2010","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"2025101408301276000_2025.10.08.681217v1.46","first-page":"2205","article-title":"Down-regulation of Deoxycytidine Kinase Enhances Acquired Resistance to Gemcitabine in Pancreatic Cancer","volume":"28","year":"2008","journal-title":"Anticancer Research"},{"key":"2025101408301276000_2025.10.08.681217v1.47","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2019.1616746"},{"key":"2025101408301276000_2025.10.08.681217v1.48","first-page":"5059","article-title":"Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response","volume":"6","year":"2014","journal-title":"Oncotarget"},{"key":"2025101408301276000_2025.10.08.681217v1.49","doi-asserted-by":"publisher","DOI":"10.1021\/jm00067a020"},{"key":"2025101408301276000_2025.10.08.681217v1.50","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1186\/s12885-021-08607-9","article-title":"Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance","volume":"21","year":"2021","journal-title":"BMC Cancer"},{"key":"2025101408301276000_2025.10.08.681217v1.51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.bjc.6606063","article-title":"Single agent and combination studies of pralatrexate and molecular correlates of sensitivity","volume":"104","year":"2011","journal-title":"Br J Cancer"},{"key":"2025101408301276000_2025.10.08.681217v1.52","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.3390\/cimb46100685","article-title":"Association of SLC19A1 Gene Polymorphisms and Its Regulatory miRNAs with Methotrexate Toxicity in Children with Acute Lymphoblastic Leukemia","volume":"46","year":"2024","journal-title":"Current Issues in Molecular Biology"},{"key":"2025101408301276000_2025.10.08.681217v1.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.022"},{"key":"2025101408301276000_2025.10.08.681217v1.54","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2438"},{"key":"2025101408301276000_2025.10.08.681217v1.55","doi-asserted-by":"crossref","first-page":"217109","DOI":"10.1016\/j.canlet.2024.217109","article-title":"SIRT7 knockdown promotes gemcitabine sensitivity of pancreatic cancer cell via upregulation of GLUT3 expression","volume":"598","year":"2024","journal-title":"Cancer Letters"},{"key":"2025101408301276000_2025.10.08.681217v1.56","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/FPC.0000000000000086","article-title":"PharmGKB summary: gemcitabine pathway","volume":"24","year":"2014","journal-title":"Pharmacogenetics and Genomics"},{"key":"2025101408301276000_2025.10.08.681217v1.57","doi-asserted-by":"crossref","unstructured":"Greenhalf, W. et al. Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. JNCI: Journal of the National Cancer Institute 106, (2014).","DOI":"10.1093\/jnci\/djt347"},{"key":"2025101408301276000_2025.10.08.681217v1.58","doi-asserted-by":"publisher","DOI":"10.1038\/nrc706"},{"key":"2025101408301276000_2025.10.08.681217v1.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-024-01402-1"},{"key":"2025101408301276000_2025.10.08.681217v1.60","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s42255-021-00486-5","article-title":"Methionine synthase is essential for cancer cell proliferation in physiological folate environments","volume":"3","year":"2021","journal-title":"Nat Metab"},{"key":"2025101408301276000_2025.10.08.681217v1.61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142997"},{"key":"2025101408301276000_2025.10.08.681217v1.62","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/s43018-023-00645-5","article-title":"Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial","volume":"4","year":"2023","journal-title":"Nat Cancer"},{"key":"2025101408301276000_2025.10.08.681217v1.63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1044-8"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.10.08.681217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:46:32Z","timestamp":1768470392000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.10.08.681217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":63,"URL":"https:\/\/doi.org\/10.1101\/2025.10.08.681217","relation":{},"subject":[],"published":{"date-parts":[[2025,10,9]]},"subtype":"preprint"}}